Diabetes, Heart and Cardiovascular Diseases News Chronicle.  Diabetes, Cardiovascular and Heart Diseases
 Article 209
    Published on June 24, 2017

Belgian Imcyse Biotech Starts Human Trials For Type 1 Diabetes Cure

Imcyse is a Belgian biotech company founded by Professor Jean-Marie Saint-Remy in July 2010. The company work is based on proprietary technology platform with the work done by its research study group based at the Catholic University of Leuven (KUL) also known as the University of Leuven, Belgium. The company is going to launch a Phase Ib trial in type 1 diabetes (T1D) patients as the company got approval from British and Belgian regulatory authorities. The European Union through EXALT program is funding the study.

The first Imcyse's immunotherapy technology trial among humans is going to be conducted in 18 sites across Belgium, Denmark, Germany, France and UK. French Inserm is the French National Institute of Health and Medical Research and Imcyse is going to collaborate with Inserm in conducting trials. Imcyse's immunotherapy technology is intended to stop the death of beta cells in the pancreas which produces insulin in patients diagnosed with type 1 diabetes (T1D). The trial results are expected during 2018.

Belgian Imcyse Biotech Starts Human Trials For Type 1 Diabetes Cure.

Existing therapies or treatments can either reduce the symptoms of type 1 diabetes (T1D) or slowdown the progress of type 1 diabetes (T1D). But immunotherapy technology from Imcyse aims to cure type 1 diabetes (T1D). Transplantation of beta cells which is under developmental stage is the other option to treat type 1 diabetes (T1D).

Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK to your social media is (copy and paste the code below) :

Articles similar to this topic

1. Breast Milk And Omega-3 Linked To Lower Risk Of Type 1 Diabetes
2. New Tool Which Can Predict No Honeymoon Phase In Children With Type 1 Diabetes
3. New Diabetes Contact Wearable Lens Solves Comfort And Vision Issues
4. Wearable Contact Lenses To Measure Blood Sugar Levels
5. About Esysta device
6. About Meizus H1 Wearable Device
7. Statins Can Reduce Risk Of Heart Attack
8. Stem Cell Plaster Could Help Heart Failure Patients



Heartisans Wearable Smartwatch Device That Can Alert Heart Attacks

Tim Lui Hin-wai, a biomedical engineer, aged 27 years co-founder of Heartisans, a Hong Kong based technology start-up company. He developed a mobile App and a Smartwatch, a wearable technology device which can predict heart attacks up to 10 minutes before it is going to happen. This device was developed specifically for heart disease and high blood pressure BP (or hypertension) patients.

The Smartwatch contains an electrocardiogram (ECG) sensor that can read heart electrical activity and pass the information to accompanying mobile App. The App analyzes the readings of the Smartwatch continuously and alerts the users about the imminent development of coronary artery disease if it is going to strike. Some of the features of the Smartwatch wearable device are

  • All readings can be viewed from the mobile App connected to the Smartwatch wearable device.
  • The device can inform the patient about the plaque buildup in the arteries causing blood clots. Plaque formation is a cardiovascular disease and called as coronary artery disease (CAD) or coronary heart disease. Formation of blood clots is the common cause of heart attacks.
  • Uses ECG and pulse sensor to measure and inform pulse transit time.
  • Shows blood pressure reading instantly.
  • Changing heartbeat rate pattern with the time can be observed. The data will be analyzed continuously by the App to alerts the users about the developing coronary artery disease before it strikes.

Heartisans Wearable Smartwatch Device That Can Alert Heart Attacks.

The wearable Smartwatch is under testing process at Queen Mary Hospital, Hong Kong with heart attack patients who experienced heart attack previously and likely to face heart attack again. Knowing the heart attack up to 10 minutes before it strikes can save a life of the patient. Tim Lui Hin-wai is planning another large trial involving 600 individuals to check congestive heart failure. They are planning to monitor the development of the congestive heart failure and effects of the treatments over the heart. Duration of the study is two years.

Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK to your social media is (copy and paste the code below) :

Articles similar to this topic

1. Wearable Technology For Elder Care
2. Wearable Devices Market
3. About Ticwatch 2 Smartwatch From Mobvoi
4. Wearable Device To Alleviate Stress and Anxiety
5. Wearable Belt Type Medical Device To Treat Diabetes In Obese Individuals
6. Transplanting Diabetic Kidneys Better Than Remaining On Waitlist
7. Ginger Fights Body Metabolic Syndrome, Fat, Obesity and Diabetes
8. Study Finds Risk Of Cardiovascular Diseases with The Combination Of Noise And Urban Traffic Air Pollution




Site maps

Site map 1   Site map 2   Site map 3   Site map 4

The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.

Published by Jammi Vasista, Chennai, India.
Email Jammi[no-space]Vasista1991[at]gmail[dot]com
Phone 91-944-578-3182.
Address Diabetes News Chronicle, No 40, Kaveri Street, Rajaji Nagar, Villivakkam, Chennai, India. Pin : 600049.